SEC Comment Letter for Neurotrope, Inc. (CIK 0001513856) — Apr 22, 2020
Neurotrope, Inc. (CIK 0001513856)
Date: April 22, 2020 · CIK: 0001513856 · Accession: 0000000000-20-003451
AI Filing Summary & Sentiment
File numbers found in text: 333-237745
Letter
April 22, 2020 Robert Weinstein Chief Financial Officer Neurotrope, Inc. 1185 Avenue of The Americas, Third Floor New York, New York 10036 Re:Neurotrope, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237745 Dear Mr. Weinstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Schultz, Esq.
Show Raw Text
April 22, 2020
Robert Weinstein
Chief Financial Officer
Neurotrope, Inc.
1185 Avenue of The Americas, Third Floor
New York, New York 10036
Re:Neurotrope, Inc.
Registration Statement on Form S-3
Filed April 17, 2020
File No. 333-237745
Dear Mr. Weinstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Schultz, Esq.